About Bolt Biotherapeutics, Inc. Common Stock
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.
Market Cap
$0.02B
Employees
100
Listed Since
February 5, 2021
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.boltbio.comPhone
650-665-9295
Headquarters
900 CHESAPEAKE DRIVE
REDWOOD CITY, CA 94063
CIK
0001641281